Depomed (DEPO) Shares are Up 1.88%

Depomed (DEPO) : Traders are bullish on Depomed (DEPO) as it has outperformed the S&P 500 by a wide margin of 19.95% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 1.71%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 1.88% in the last 1 week, and is up 19.3% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The stock has recorded a 20-day Moving Average of 8.92% and the 50-Day Moving Average is 17.23%.The 200 Day SMA reached 36.89%


Depomed (NASDAQ:DEPO): After opening at $23.9, the stock dipped to an intraday low of $23.5429 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $27.0199 and the buying power remained strong till the end. The stock closed at $24.9699 for the day, a gain of 4.52% for the day session. The total traded volume was 2,101,433. The stocks close on the previous trading day was $24.9699.

Depomed (DEPO) : The consensus price target for Depomed (DEPO) is $23.36 for the short term with a standard deviation of $4.59. The most optimist securities analyst among the 11 who monitor the stock believes that the stock can reach $30, however, the pessimist price target for the company is $14.

Depomed, Inc. is a specialty pharmaceutical company focused on pain and other central nervous system (CNS) conditions. The Companys products include Gralise (gabapentin), CAMBIA (diclofenac potassium for oral solution), Zipsor (diclofenac potassium) and Lazanda (fentanyl). Gralise is a once-daily product for the management of postherpetic neuralgia (PHN). CAMBIA is a non-steroidal anti-inflammatory drug (NSAID) for the acute treatment of migraine attacks. Zipsor, a liquid filled capsule, is a NSAID for the treatment of mild to moderate acute pain. Lazanda nasal spray is used for the management of break through pain in cancer patients 18 years of age and older who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. It also has a portfolio of license agreements based on its Acuform gastroretentive drug delivery technology. The Companys product DM-1992 has completed a Phase II trial for Parkinsons disease.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *